Dr. Reddy's Laboratories Ltd (RDY) 46.94 $RDY D
Post# of 273257
Posted On: 09/05/2016 1:02:02 PM
Dr. Reddy's Laboratories Ltd (RDY) 46.94 $RDY
Dr. Reddy's Laboratories Announces the Launch of Bupropion HCl Extended-Release Tablets, USP (SR) in the U.S. Market
BusinessWire - Fri Sep 02, 10:32AM CDT
Dr. Reddy's Laboratories Ltd (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced today that it has launched Bupropion HCl extended-release tablets, USP (SR) in 100 mg, 150 mg and 200 mg, a therapeutic equivalent generic version of Wellbutrin(R) SR (bupropion HCl) Sustained-Release Tablets in the United States market approved by the U.S. Food & Drug Administration (USFDA).
RDY: 46.94 (+0.90)
Dr. Reddy's Announces Purple Health, a Unique Patient-Centric Platform That Takes Care beyond the Pill
BusinessWire - Thu Sep 01, 4:43AM CDT
Dr. Reddy's Laboratories Ltd (BSE: 500124, NSE: DRREDDY, NYSE: RDY) today announced the launch of Purple Health, a unique platform designed to inspire patient-centric innovation and deliver solutions that address unmet needs of patients. Built around four pillars of Awareness, Access, Adherence and Experience of therapy for patients, Purple Health is another affirmative step forward by Dr. Reddy's to institutionalize patient-centricity across the organization, stemming from its core belief 'Good Health Can't Wait.'
RDY: 46.94 (+0.90)
Dr. Reddy's Laboratories Launches Nitroglycerin Sublingual Tablets USP in the U.S. Market Hyderabad, India, August 29, 2016
BusinessWire - Mon Aug 29, 4:23AM CDT
Dr. Reddy's Laboratories Ltd (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced today that it has launched Nitroglycerin sublingual tablets USP, 0.3 mg, 0.4 mg and 0.6 mg, a therapeutic equivalent generic version of Nitrostat(R) (Nitroglycerin) sublingual tablets in the US market on August 26, 2016, having been approved by the United States Food & Drug Administration (USFDA).
RDY: 46.94 (+0.90)
Look for Shares of Dr Reddys Laboratories to Potentially Pullback after Yesterday's 1.23% Rise
Comtex SmarTrend(R) - Thu Aug 25, 3:11PM CDT
Dr Reddys Laboratories (NYSE:RDY) traded in a range yesterday that spanned from a low of $45.62 to a high of $46.00. Yesterday, the shares gained 1.2%, which took the trading range above the 3-day high of $45.96 on volume of 75,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
RDY: 46.94 (+0.90)
New Strong Sell Stocks for August 24th
Zacks Equity Research - Zacks Investment Research - Wed Aug 24, 9:52AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Wednesday
EMN: 68.58 (+0.81), GGG: 75.07 (+1.86), RDY: 46.94 (+0.90), CSIQ: 13.14 (+0.17), ALGT: 136.37 (-0.04)
Dr. Reddy's Completes Acquisition of Product Portfolio from TEVA
BusinessWire - Wed Aug 03, 12:58PM CDT
Dr. Reddy's Laboratories Ltd. (BSE: 500124) (NSE: DRREDDY) (NYSE: RDY) today announced that it successfully completed the previously announced acquisition of eight Abbreviated New Drug Applications (ANDAs) in the U.S. from Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) (TASE: TEVA) and an affiliate of Allergan plc (NYSE: AGN). The acquired portfolio consists of products that are being divested by Teva as a precondition to its closing of the acquisition of Allergan's generics business.
AGN: 235.96 (-1.80), TEVA: 51.22 (+0.32), RDY: 46.94 (+0.90)
New Strong Sell Stocks for July 28th
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 7:57AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Thursday
OSB: 25.17 (+0.55), FCH: 6.88 (unch), WFC: 50.55 (+0.12), RDY: 46.94 (+0.90), WAB: 76.66 (+0.87)
Downgrade Alert for Dr Reddys Laboratories (RDY)
Comtex SmarTrend(R) - Thu Jul 28, 3:46AM CDT
Dr Reddys Laboratories (NYSE:RDY) was downgraded from Neutral to Underperform at Credit Suisse today. The stock closed yesterday at $43.82 on volume of 801,000 shares, above average daily volume of 303,000. In the past 52 weeks, Dr Reddys Laboratories share prices have been bracketed by a low of $40.68 and a high of $68.00 and closed yesterday at $43.82, 8% above that low price. Over the past week, the 200-day moving average (MA) has gone down 0.7% while the 50-day MA has remained constant.
RDY: 46.94 (+0.90)
Dr. Reddy's to acquire product portfolio from TEVA for US Market
BusinessWire - Sat Jun 11, 8:26AM CDT
Dr. Reddy's Laboratories (BSE:500124, NSE
RREDDY, NYSE:RDY) has entered into a definitive agreement with Teva Pharmaceutical Industries Ltd. (NYSE and TASE:TEVA) and an affiliate of Allergan plc (NYSE:AGN)to acquire a portfolio of eight Abbreviated New Drug Applications (ANDAs) in the U.S. for $350 million in cash at closing. The acquired portfolio consists of products that are being divested by Teva as a precondition to its closing of the acquisition of Allergan's generics business. The acquisition of these ANDAs is also contingent on the closing of the Teva/Allergan generics transaction and approval by the U.S. Federal Trade Commission of Dr. Reddy's as a buyer.
AGN: 235.96 (-1.80), RDY: 46.94 (+0.90)
Promius Pharma Launches Sernivo(TM) (betamethasone dipropionate) Spray, 0.05%
BusinessWire - Wed Jun 01, 1:48AM CDT
Dr. Reddy's Laboratories announced today that its US subsidiary, Promius Pharma, LLC, U.S. (BSE: 500124, NSE: DRREDDY, NYSE: RDY), launched Sernivo(TM) (betamethasone dipropionate) Spray, 0.05% in the U.S. Sernivo Spray, a prescription topical steroid approved by the Food and Drug Administration (FDA) in February of 2016, is indicated for the treatment of mild to moderate plaque psoriasis in patients 18 years of age or older.
RDY: 46.94 (+0.90)
Dr. Reddy's (RDY) Acquires Ducere Pharma's OTC Brands
Zacks Equity Research - Zacks Investment Research - Thu May 26, 2:57PM CDT
Dr. Reddy's Laboratories Ltd. (RDY) announced that it acquired a portfolio of OTC brands in the cough-and-cold, pain, and dermatology categories from Ducere Pharma.
ABT: 42.09 (-0.21), JNJ: 119.32 (+0.24), RDY: 46.94 (+0.90)
Dr. Reddy's Enters the Branded Consumer Health Arena Through the Acquisition of Six OTC Brands
BusinessWire - Wed May 25, 5:47AM CDT
Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) today announced the acquisition of an eminent portfolio of over-the-counter (OTC) brands in the cough-and-cold, pain, and dermatology categories. The company acquired six OTC brands from Ducere Pharma, including DOAN'S(R), BUFFERIN(R), NUPERCAINAL(R) Ointment, CRUEX(R) Nail Gel, COMTREX(R), and MYOFLEX(R).
RDY: 46.94 (+0.90)
Dr. Reddy's Q4 and FY16 Financial Results
BusinessWire - Thu May 12, 5:47AM CDT
--Q4 EBITDA at Rs. 4.8 billion(12.8% of the revenues)
RDY: 46.94 (+0.90)
Dr. Reddy's Laboratories Announces the Appointment of Mr. Bharat Doshi as an Additional Independent Director on the Board of the Company
BusinessWire - Wed May 11, 12:14PM CDT
Mr. Bharat Doshi has been appointed as an Additional Independent Director on the Board of Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY), effective May 11, 2016.
RDY: 46.94 (+0.90)
Drug Stocks' Earnings Slated for This Week: RDY, AVXS, ESALY
Zacks Equity Research - Zacks Investment Research - Wed May 11, 9:03AM CDT
Quite a few companies are still yet to report results. Let's take a peek at a few drug stocks that will report quarterly results later this week
JNJ: 119.32 (+0.24), GILD: 76.89 (-0.53), PFE: 34.77 (+0.09), AMGN: 169.77 (-0.36), ABBV: 64.12 (+0.09), RDY: 46.94 (+0.90), AVXS: 34.60 (+0.07), NVS: 79.38 (+1.11)
Dr. Reddy's to Release Q4 and Full Year FY16 Results on May 12, 2016; Earnings Call Slated for May 12, 6.30 PM IST / 9.00 AM EDT
BusinessWire - Tue Apr 26, 6:34AM CDT
Dr. Reddy's Laboratories (NYSE: RDY; NSE: DRREDDY; BSE: 500124) will announce results for the Fourth Quarter and Full Year ended March 31, 2016 on Thursday, May 12, 2016 after the Board Meeting. The results will be available on the Company's website www.drreddys.com.
RDY: 46.94 (+0.90)
ZEMBRACE(TM) SymTouch(TM) (Sumatriptan Injection) 3 mg, Approved by the FDA in January 2016 for the Acute Treatment of Migraine with or without Aura in Adults, is Now Commercially Available in the U.S.
BusinessWire - Tue Apr 19, 4:12AM CDT
Promius Pharma LLC, a subsidiary of Dr. Reddy's Laboratories (BSE: 500124, NSE: DRREDDY, NYSE: RDY), announced today that ZEMBRACE SymTouchis now commercially available in the U.S.
RDY: 46.94 (+0.90)
Cutispharma, Dr. Reddy's Laboratories Announce Partnership
PR Newswire - Tue Apr 05, 5:00AM CDT
CutisPharma, a specialty pharmaceutical company that has historically developed and distributed kits used by pharmacists to safely create compounded medications, announced today that it is entering into Active Pharmaceutical Ingredient (API) supply and joint development agreements with Dr. Reddy's Laboratories Ltd. to advance several programs in CutisPharma's R&D portfolio, including RM-02, RM-03, and RM-06, toward FDA approval.
RDY: 46.94 (+0.90)
Dr. Reddy's Laboratories Announces the Launch of Bupropion HCl Extended-Release Tablets, USP (SR) in the U.S. Market
BusinessWire - Fri Sep 02, 10:32AM CDT
Dr. Reddy's Laboratories Ltd (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced today that it has launched Bupropion HCl extended-release tablets, USP (SR) in 100 mg, 150 mg and 200 mg, a therapeutic equivalent generic version of Wellbutrin(R) SR (bupropion HCl) Sustained-Release Tablets in the United States market approved by the U.S. Food & Drug Administration (USFDA).
RDY: 46.94 (+0.90)
Dr. Reddy's Announces Purple Health, a Unique Patient-Centric Platform That Takes Care beyond the Pill
BusinessWire - Thu Sep 01, 4:43AM CDT
Dr. Reddy's Laboratories Ltd (BSE: 500124, NSE: DRREDDY, NYSE: RDY) today announced the launch of Purple Health, a unique platform designed to inspire patient-centric innovation and deliver solutions that address unmet needs of patients. Built around four pillars of Awareness, Access, Adherence and Experience of therapy for patients, Purple Health is another affirmative step forward by Dr. Reddy's to institutionalize patient-centricity across the organization, stemming from its core belief 'Good Health Can't Wait.'
RDY: 46.94 (+0.90)
Dr. Reddy's Laboratories Launches Nitroglycerin Sublingual Tablets USP in the U.S. Market Hyderabad, India, August 29, 2016
BusinessWire - Mon Aug 29, 4:23AM CDT
Dr. Reddy's Laboratories Ltd (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced today that it has launched Nitroglycerin sublingual tablets USP, 0.3 mg, 0.4 mg and 0.6 mg, a therapeutic equivalent generic version of Nitrostat(R) (Nitroglycerin) sublingual tablets in the US market on August 26, 2016, having been approved by the United States Food & Drug Administration (USFDA).
RDY: 46.94 (+0.90)
Look for Shares of Dr Reddys Laboratories to Potentially Pullback after Yesterday's 1.23% Rise
Comtex SmarTrend(R) - Thu Aug 25, 3:11PM CDT
Dr Reddys Laboratories (NYSE:RDY) traded in a range yesterday that spanned from a low of $45.62 to a high of $46.00. Yesterday, the shares gained 1.2%, which took the trading range above the 3-day high of $45.96 on volume of 75,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
RDY: 46.94 (+0.90)
New Strong Sell Stocks for August 24th
Zacks Equity Research - Zacks Investment Research - Wed Aug 24, 9:52AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Wednesday
EMN: 68.58 (+0.81), GGG: 75.07 (+1.86), RDY: 46.94 (+0.90), CSIQ: 13.14 (+0.17), ALGT: 136.37 (-0.04)
Dr. Reddy's Completes Acquisition of Product Portfolio from TEVA
BusinessWire - Wed Aug 03, 12:58PM CDT
Dr. Reddy's Laboratories Ltd. (BSE: 500124) (NSE: DRREDDY) (NYSE: RDY) today announced that it successfully completed the previously announced acquisition of eight Abbreviated New Drug Applications (ANDAs) in the U.S. from Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) (TASE: TEVA) and an affiliate of Allergan plc (NYSE: AGN). The acquired portfolio consists of products that are being divested by Teva as a precondition to its closing of the acquisition of Allergan's generics business.
AGN: 235.96 (-1.80), TEVA: 51.22 (+0.32), RDY: 46.94 (+0.90)
New Strong Sell Stocks for July 28th
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 7:57AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Thursday
OSB: 25.17 (+0.55), FCH: 6.88 (unch), WFC: 50.55 (+0.12), RDY: 46.94 (+0.90), WAB: 76.66 (+0.87)
Downgrade Alert for Dr Reddys Laboratories (RDY)
Comtex SmarTrend(R) - Thu Jul 28, 3:46AM CDT
Dr Reddys Laboratories (NYSE:RDY) was downgraded from Neutral to Underperform at Credit Suisse today. The stock closed yesterday at $43.82 on volume of 801,000 shares, above average daily volume of 303,000. In the past 52 weeks, Dr Reddys Laboratories share prices have been bracketed by a low of $40.68 and a high of $68.00 and closed yesterday at $43.82, 8% above that low price. Over the past week, the 200-day moving average (MA) has gone down 0.7% while the 50-day MA has remained constant.
RDY: 46.94 (+0.90)
Dr. Reddy's to acquire product portfolio from TEVA for US Market
BusinessWire - Sat Jun 11, 8:26AM CDT
Dr. Reddy's Laboratories (BSE:500124, NSE
RREDDY, NYSE:RDY) has entered into a definitive agreement with Teva Pharmaceutical Industries Ltd. (NYSE and TASE:TEVA) and an affiliate of Allergan plc (NYSE:AGN)to acquire a portfolio of eight Abbreviated New Drug Applications (ANDAs) in the U.S. for $350 million in cash at closing. The acquired portfolio consists of products that are being divested by Teva as a precondition to its closing of the acquisition of Allergan's generics business. The acquisition of these ANDAs is also contingent on the closing of the Teva/Allergan generics transaction and approval by the U.S. Federal Trade Commission of Dr. Reddy's as a buyer. AGN: 235.96 (-1.80), RDY: 46.94 (+0.90)
Promius Pharma Launches Sernivo(TM) (betamethasone dipropionate) Spray, 0.05%
BusinessWire - Wed Jun 01, 1:48AM CDT
Dr. Reddy's Laboratories announced today that its US subsidiary, Promius Pharma, LLC, U.S. (BSE: 500124, NSE: DRREDDY, NYSE: RDY), launched Sernivo(TM) (betamethasone dipropionate) Spray, 0.05% in the U.S. Sernivo Spray, a prescription topical steroid approved by the Food and Drug Administration (FDA) in February of 2016, is indicated for the treatment of mild to moderate plaque psoriasis in patients 18 years of age or older.
RDY: 46.94 (+0.90)
Dr. Reddy's (RDY) Acquires Ducere Pharma's OTC Brands
Zacks Equity Research - Zacks Investment Research - Thu May 26, 2:57PM CDT
Dr. Reddy's Laboratories Ltd. (RDY) announced that it acquired a portfolio of OTC brands in the cough-and-cold, pain, and dermatology categories from Ducere Pharma.
ABT: 42.09 (-0.21), JNJ: 119.32 (+0.24), RDY: 46.94 (+0.90)
Dr. Reddy's Enters the Branded Consumer Health Arena Through the Acquisition of Six OTC Brands
BusinessWire - Wed May 25, 5:47AM CDT
Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) today announced the acquisition of an eminent portfolio of over-the-counter (OTC) brands in the cough-and-cold, pain, and dermatology categories. The company acquired six OTC brands from Ducere Pharma, including DOAN'S(R), BUFFERIN(R), NUPERCAINAL(R) Ointment, CRUEX(R) Nail Gel, COMTREX(R), and MYOFLEX(R).
RDY: 46.94 (+0.90)
Dr. Reddy's Q4 and FY16 Financial Results
BusinessWire - Thu May 12, 5:47AM CDT
--Q4 EBITDA at Rs. 4.8 billion(12.8% of the revenues)
RDY: 46.94 (+0.90)
Dr. Reddy's Laboratories Announces the Appointment of Mr. Bharat Doshi as an Additional Independent Director on the Board of the Company
BusinessWire - Wed May 11, 12:14PM CDT
Mr. Bharat Doshi has been appointed as an Additional Independent Director on the Board of Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY), effective May 11, 2016.
RDY: 46.94 (+0.90)
Drug Stocks' Earnings Slated for This Week: RDY, AVXS, ESALY
Zacks Equity Research - Zacks Investment Research - Wed May 11, 9:03AM CDT
Quite a few companies are still yet to report results. Let's take a peek at a few drug stocks that will report quarterly results later this week
JNJ: 119.32 (+0.24), GILD: 76.89 (-0.53), PFE: 34.77 (+0.09), AMGN: 169.77 (-0.36), ABBV: 64.12 (+0.09), RDY: 46.94 (+0.90), AVXS: 34.60 (+0.07), NVS: 79.38 (+1.11)
Dr. Reddy's to Release Q4 and Full Year FY16 Results on May 12, 2016; Earnings Call Slated for May 12, 6.30 PM IST / 9.00 AM EDT
BusinessWire - Tue Apr 26, 6:34AM CDT
Dr. Reddy's Laboratories (NYSE: RDY; NSE: DRREDDY; BSE: 500124) will announce results for the Fourth Quarter and Full Year ended March 31, 2016 on Thursday, May 12, 2016 after the Board Meeting. The results will be available on the Company's website www.drreddys.com.
RDY: 46.94 (+0.90)
ZEMBRACE(TM) SymTouch(TM) (Sumatriptan Injection) 3 mg, Approved by the FDA in January 2016 for the Acute Treatment of Migraine with or without Aura in Adults, is Now Commercially Available in the U.S.
BusinessWire - Tue Apr 19, 4:12AM CDT
Promius Pharma LLC, a subsidiary of Dr. Reddy's Laboratories (BSE: 500124, NSE: DRREDDY, NYSE: RDY), announced today that ZEMBRACE SymTouchis now commercially available in the U.S.
RDY: 46.94 (+0.90)
Cutispharma, Dr. Reddy's Laboratories Announce Partnership
PR Newswire - Tue Apr 05, 5:00AM CDT
CutisPharma, a specialty pharmaceutical company that has historically developed and distributed kits used by pharmacists to safely create compounded medications, announced today that it is entering into Active Pharmaceutical Ingredient (API) supply and joint development agreements with Dr. Reddy's Laboratories Ltd. to advance several programs in CutisPharma's R&D portfolio, including RM-02, RM-03, and RM-06, toward FDA approval.
RDY: 46.94 (+0.90)
(0)
(0)Scroll down for more posts ▼